Nutra Pharma Corp (NPHC) Receivables (2010 - 2026)

Nutra Pharma has disclosed Receivables across 17 years of filings, most recently posting $334186.0 for Q2 2026.

• In Q2 2026, Receivables rose 103.61% year-over-year to $334186.0; the TTM figure through Jun 2026 stood at $334186.0 (up 103.61% YoY), while the FY2025 annual figure was $319907.0, up 246.76% from the prior year.
• Receivables came in at $334186.0 for Q2 2026 at Nutra Pharma, up from $160251.0 in the prior quarter.
• In the past five years, Receivables ranged from a high of $334186.0 in Q2 2026 to a low of $18149.0 in Q3 2024.
• Average Receivables over 5 years is $91027.9, with a median of $54530.0 recorded in 2022.
• Year-over-year, Receivables plunged 94.9% in 2022 and surged 854.4% in 2025.
• Over 5 years, Receivables stood at $24664.0 in 2022, then advanced by 7.17% to $26433.0 in 2023, then surged by 99.22% to $52661.0 in 2024, then rose by 6.45% to $56060.0 in 2025, then jumped by 496.12% to $334186.0 in 2026.
• Per Business Quant data, the three most recent Receivables figures were $334186.0 in Q2 2026, $160251.0 in Q1 2026, and $56060.0 in Q4 2025.